106 related articles for article (PubMed ID: 23898050)
1. Antineoplastic activity of zoledronic acid and denosumab.
Zwolak P; Dudek AZ
Anticancer Res; 2013 Aug; 33(8):2981-8. PubMed ID: 23898050
[TBL] [Abstract][Full Text] [Related]
2. Anticancer properties of zoledronic acid.
Green J; Lipton A
Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Wong KC; Kumta SM
Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
[TBL] [Abstract][Full Text] [Related]
4. Denosumab and bone metastases. No better than a bisphosphonate.
Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
[TBL] [Abstract][Full Text] [Related]
5. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.
Rolfo C; Raez LE; Russo A; Reguart N; Campelo RG; Bronte G; Papadimitriou K; Silvestris F
Expert Opin Biol Ther; 2014 Jan; 14(1):15-26. PubMed ID: 24161019
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptive therapies in oncology and their effects on cancer progression.
Bundred N
Cancer Treat Rev; 2012 Oct; 38(6):776-86. PubMed ID: 22370427
[TBL] [Abstract][Full Text] [Related]
7. Effects of bone-targeted agents on cancer progression and mortality.
Coleman R; Gnant M; Morgan G; Clezardin P
J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
[TBL] [Abstract][Full Text] [Related]
8. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
11. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
Carter JA; Botteman MF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167
[TBL] [Abstract][Full Text] [Related]
12. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
[TBL] [Abstract][Full Text] [Related]
13. Denosumab and bisphosphonates: different mechanisms of action and effects.
Baron R; Ferrari S; Russell RG
Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
[TBL] [Abstract][Full Text] [Related]
14. Role of denosumab in prostate cancer.
Helo S; Manger JP; Krupski TL
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):231-6. PubMed ID: 22370723
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
18. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
Lipton A; Balakumaran A
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
[TBL] [Abstract][Full Text] [Related]
19. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908
[TBL] [Abstract][Full Text] [Related]
20. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]